Eli Lilly to buy Loxo Oncology for $8bn in cancer drug push
① Eli Lilly has agreed to splash out $8bn on smaller rival Loxo Oncology, the latest in a series of multibillion-dollar pharmaceutical deals as traditional drugmakers buttress cancer treatment portfolios with novel therapies that have been proven effective in treating the disease. ② The contest for supremacy in oncology has been long running among the biggest pharmaceutical groups, with acquisitions and research and development dollars centred on new gene therapies that harness the body's immune system to fight the disease. ③ Loxo Oncology's portfolio of inhibitors targeted specifically to patients with mutations or fusions in these genes, in combination with advanced diagnostics that allow us to know exactly which patients may benefit, creates new opportunities to improve the lives of people with advanced cancer. ④ The Loxo portfolio includes several drugs that are in trial as well as at least one that has been approved for use in patients, known as Vitrakvi.
迩到来，美国礼到来公司（Eli Lilly and Company）赞同以80亿美元即兴金收买进 Loxo Oncology 公司，父亲顺手笔押注治水疗某种特定基因急变伸发的癌症药品，此雕刻亦礼到来143年历史上最父亲的壹笔收买进案。 礼到来公司是壹家全球性的以研发为基础的医药公司，亦世界什父亲肿瘤治水疗公司之壹。Loxo 固然规模较小，但在抗癌药范畴却是壹家名副实则的皓星企业——2018年11月底儿子，Loxo 得到了美国食品药品监督办局（FDA）同意的壹款名为 Vitrakvi 的药物，该药物被证皓对由某种特定基因急变伸发的癌症拥有疗效，是癌症治水疗由片面打击到稀准打击的要紧转变。 此雕刻笔买进卖壹方面标注识表记标注帜着礼到来正从传统糖尿病治水疗扩展到火线基因治水疗范畴，另壹方面无论是从医药巨万头的变募化还是整顿个行业的趋势到来看，医学曾经走到壹个什分要紧的转折点点。